Nexgel Inc Financials
Nexgel Inc (NXGL) reported $11.4M in revenue for fiscal year 2025, up 31.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth is widening gross margins, but rising overhead and working-capital needs keep the company cash-consuming.
From FY2023 to FY2025, gross margin rose from9.2% to39.5% , showing a major improvement in the economics of each dollar sold. Yet operating loss remained about$3.4M in FY2025 while SG&A reached$7.9M , so gross-profit gains were absorbed by overhead rather than reaching the bottom line.
Cash conversion is improving: operating cash flow narrowed from
Cash fell to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Nexgel Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nexgel Inc scores -2.27, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($3.2M) relative to total liabilities ($5.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Nexgel Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Nexgel Inc reported a net loss of $3.0M while operations used $1.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Nexgel Inc reported an operating loss of $3.4M against $34K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Nexgel Inc generated $11.4M in revenue in fiscal year 2025. This represents an increase of 31.5% from the prior year.
Nexgel Inc's EBITDA was -$2.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 6.9% from the prior year.
Nexgel Inc reported -$3.0M in net income in fiscal year 2025. This represents an increase of 8.6% from the prior year.
Nexgel Inc earned -$0.38 per diluted share (EPS) in fiscal year 2025. This represents an increase of 24.0% from the prior year.
Cash & Balance Sheet
Nexgel Inc recorded an outflow of $1.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 68.0% from the prior year.
Nexgel Inc held $317K in cash against $588K in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Nexgel Inc's gross margin was 39.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 7.8 percentage points from the prior year.
Nexgel Inc's operating margin was -29.3% in fiscal year 2025, reflecting core business profitability. This is up 11.6 percentage points from the prior year.
Nexgel Inc's net profit margin was -26.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 11.5 percentage points from the prior year.
Nexgel Inc's ROE was -67.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 10.2 percentage points from the prior year.
Capital Allocation
Nexgel Inc invested $2K in research and development in fiscal year 2025. This represents a decrease of 97.4% from the prior year.
Nexgel Inc invested $68K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 84.7% from the prior year.
Not reported for fiscal year 2025.
NXGL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.1M | $11.4M+31.5% | $8.7M+112.5% | $4.1M+99.7% | $2.0M+32.0% | $1.6M+130.1% | $674K-6.0% | $717K-67.6% | $2.2M |
| Cost of Revenue | $7.8M | $6.9M+16.4% | $5.9M+59.9% | $3.7M+107.3% | $1.8M+16.1% | $1.5M+59.9% | $965K+13.0% | $854K-49.7% | $1.7M |
| Gross Profit | $4.2M | $4.5M+64.1% | $2.7M+634.8% | $374K+46.1% | $256K+3100.0% | $8K+102.7% | -$291K-112.4% | -$137K-126.7% | $514K |
| R&D Expenses | N/A | $2K-97.4% | $78K-24.3% | $103K-71.9% | $367K+1083.9% | $31K | N/A | N/A | N/A |
| SG&A Expenses | $9.6M | $7.9M+26.3% | $6.2M+66.1% | $3.7M+15.8% | $3.2M+27.1% | $2.5M+29.4% | $2.0M+10.2% | $1.8M-25.6% | $2.4M |
| Operating Income | -$5.4M | -$3.4M+5.7% | -$3.6M-2.2% | -$3.5M-3.9% | -$3.3M-30.3% | -$2.6M-13.7% | -$2.3M-17.5% | -$1.9M-1.9% | -$1.9M |
| Interest Expense | N/A | $34K-58.0% | $81K+440.0% | $15K-98.9% | $1.3M | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 | N/A |
| Net Income | -$6.2M | -$3.0M+8.6% | -$3.3M-3.9% | -$3.2M+33.5% | -$4.7M-10.1% | -$4.3M-90.4% | -$2.3M-17.7% | -$1.9M-1.9% | -$1.9M |
| EPS (Diluted) | — | -$0.38+24.0% | -$0.50+10.7% | -$0.56+34.1% | -$0.85 | -$1.45 | -$1.05 | -$0.14 | -$0.38 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NXGL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.5M-4.8% | $11.0M+10.3% | $10.0M-3.9% | $10.4M-39.0% | $17.0M+652.5% | $2.3M+19.4% | $1.9M+155.8% | $739K |
| Current Assets | $4.3M-15.2% | $5.1M+1.2% | $5.1M-32.7% | $7.5M-46.1% | $13.9M+3736.6% | $363K-29.2% | $513K+42.1% | $361K |
| Cash & Equivalents | $317K-82.5% | $1.8M-33.1% | $2.7M+145.2% | $1.1M-91.8% | $13.3M+41618.8% | $32K-87.7% | $261K | $0 |
| Inventory | $2.1M+20.6% | $1.8M+32.8% | $1.3M+162.7% | $502K+72.5% | $291K+24.9% | $233K+106.2% | $113K+11.9% | $101K |
| Accounts Receivable | $673K-27.9% | $933K+47.4% | $633K+185.1% | $222K+6.2% | $209K+186.3% | $73K-28.4% | $102K+200.0% | $34K |
| Goodwill | $1.1M0.0% | $1.1M0.0% | $1.1M+262.7% | $311K0.0% | $311K0.0% | $311K | $0 | N/A |
| Total Liabilities | $5.6M+13.6% | $4.9M+2.4% | $4.8M+76.1% | $2.7M-44.5% | $4.9M+124.1% | $2.2M+44.8% | $1.5M+229.7% | $458K |
| Current Liabilities | $3.0M+19.7% | $2.5M-3.1% | $2.5M+196.7% | $859K-70.3% | $2.9M+116.8% | $1.3M+66.5% | $800K+96.6% | $407K |
| Long-Term Debt | $588K-14.2% | $685K+15.5% | $593K+109.5% | $283K | N/A | N/A | N/A | N/A |
| Total Equity | $4.5M-22.5% | $5.8M+22.5% | $4.7M-38.5% | $7.6M-36.8% | $12.1M+16921.1% | $71K-81.3% | $380K+35.2% | $281K |
| Retained Earnings | -$21.0M-16.7% | -$18.0M-22.3% | -$14.7M-27.3% | -$11.6M-69.7% | -$6.8M-172.3% | -$2.5M-951.3% | -$238K | $0 |
NXGL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M | -$1.3M+66.1% | -$3.9M-19.5% | -$3.2M-8.2% | -$3.0M-8.7% | -$2.8M-52.9% | -$1.8M+0.7% | -$1.8M-17.5% | -$1.5M |
| Capital Expenditures | N/A | $68K-84.7% | $443K-36.4% | $696K+625.0% | $96K-64.3% | $269K-13.8% | $312K | $0 | N/A |
| Free Cash Flow | N/A | -$1.4M+68.0% | -$4.3M-9.6% | -$3.9M-27.3% | -$3.1M-2.2% | -$3.0M-43.0% | -$2.1M-16.5% | -$1.8M | N/A |
| Investing Cash Flow | -$6.6M | -$68K+91.2% | -$775K-117.4% | $4.5M+179.6% | -$5.6M-1979.9% | -$269K+13.8% | -$312K | $0 | N/A |
| Financing Cash Flow | $10.8M | $630K-83.2% | $3.7M+889.2% | $379K+110.3% | -$3.7M-122.4% | $16.3M+767.3% | $1.9M-9.2% | $2.1M+34.4% | $1.5M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NXGL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.5%+7.8pp | 31.6%+22.5pp | 9.2%-3.4pp | 12.5%+12.0pp | 0.5%+43.7pp | -43.2%-24.1pp | -19.1%-42.3pp | 23.2% |
| Operating Margin | -29.3%+11.6pp | -40.9%+44.1pp | -85.0% | -163.5% | -165.7% | -335.3% | -268.3% | -85.3% |
| Net Margin | -26.3%+11.5pp | -37.8%+39.5pp | -77.2% | -231.7% | -277.9% | -335.9% | -268.2% | -85.3% |
| Return on Equity | -67.3%-10.2pp | -57.0%+10.2pp | -67.2%-5.1pp | -62.1%-26.5pp | -35.7%+3153.1pp | -3188.7%-2682.7pp | -506.1%+165.8pp | -671.9% |
| Return on Assets | -28.7%+1.2pp | -29.9%+1.8pp | -31.7%+14.1pp | -45.8%-20.4pp | -25.4%+74.9pp | -100.3%+1.4pp | -101.8%+153.7pp | -255.5% |
| Current Ratio | 1.47-0.6x | 2.07+0.1x | 1.98-6.8x | 8.74+3.9x | 4.82+4.5x | 0.27-0.4x | 0.64-0.2x | 0.89 |
| Debt-to-Equity | 0.130.0x | 0.120.0x | 0.13+0.1x | 0.04-0.4x | 0.41-30.4x | 30.79+26.8x | 3.97+2.3x | 1.63 |
| FCF Margin | -12.1%+37.5pp | -49.6%+46.6pp | -96.2% | -150.8% | -194.8% | -313.5% | -253.0% | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Nexgel Inc Ranks
Frequently Asked Questions
What is Nexgel Inc's annual revenue?
Nexgel Inc (NXGL) reported $11.4M in total revenue for fiscal year 2025. This represents a 31.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nexgel Inc's revenue growing?
Nexgel Inc (NXGL) revenue grew by 31.5% year-over-year, from $8.7M to $11.4M in fiscal year 2025.
Is Nexgel Inc profitable?
No, Nexgel Inc (NXGL) reported a net income of -$3.0M in fiscal year 2025, with a net profit margin of -26.3%.
What is Nexgel Inc's EBITDA?
Nexgel Inc (NXGL) had EBITDA of -$2.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Nexgel Inc have?
As of fiscal year 2025, Nexgel Inc (NXGL) had $317K in cash and equivalents against $588K in long-term debt.
What is Nexgel Inc's gross margin?
Nexgel Inc (NXGL) had a gross margin of 39.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Nexgel Inc's operating margin?
Nexgel Inc (NXGL) had an operating margin of -29.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Nexgel Inc's net profit margin?
Nexgel Inc (NXGL) had a net profit margin of -26.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Nexgel Inc's return on equity (ROE)?
Nexgel Inc (NXGL) has a return on equity of -67.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nexgel Inc's free cash flow?
Nexgel Inc (NXGL) recorded an outflow of $1.4M in free cash flow during fiscal year 2025. This represents a 68.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nexgel Inc's operating cash flow?
Nexgel Inc (NXGL) recorded an outflow of $1.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Nexgel Inc's total assets?
Nexgel Inc (NXGL) had $10.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nexgel Inc's capital expenditures?
Nexgel Inc (NXGL) invested $68K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Nexgel Inc spend on research and development?
Nexgel Inc (NXGL) invested $2K in research and development during fiscal year 2025.
What is Nexgel Inc's current ratio?
Nexgel Inc (NXGL) had a current ratio of 1.47 as of fiscal year 2025, which is considered adequate.
What is Nexgel Inc's debt-to-equity ratio?
Nexgel Inc (NXGL) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nexgel Inc's return on assets (ROA)?
Nexgel Inc (NXGL) had a return on assets of -28.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nexgel Inc's cash runway?
Based on fiscal year 2025 data, Nexgel Inc (NXGL) had $317K in cash against an annual operating cash burn of $1.3M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Nexgel Inc's Altman Z-Score?
Nexgel Inc (NXGL) has an Altman Z-Score of -2.27, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Nexgel Inc's Piotroski F-Score?
Nexgel Inc (NXGL) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nexgel Inc's earnings high quality?
Nexgel Inc (NXGL) reported a net loss of $3.0M while operations used $1.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Nexgel Inc cover its interest payments?
Nexgel Inc (NXGL) reported an operating loss of $3.4M against $34K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Nexgel Inc?
Nexgel Inc (NXGL) scores 38 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.